Radiotherapy & Oncology
Volume 93, Issue 3 , Pages 468-473 , December 2009

Reverse resistance to radiation in KYSE-150R esophageal carcinoma cell after epidermal growth factor receptor signal pathway inhibition by cetuximab

  • Zhao Jing

      Affiliations

    • Department of Radiation Oncology, The First Affiliated Hospital of Wenzhou Medical College, China
    • ,
  • Ling Gong

      Affiliations

    • Department of Infection and Liver Diseases, The First Affiliated Hospital of Wenzhou Medical College, China
    • ,
  • Cong-Ying Xie

      Affiliations

    • Department of Radiation Oncology, The First Affiliated Hospital of Wenzhou Medical College, China
    • ,
  • Li Zhang

      Affiliations

    • Department of Radiation Oncology, The First Affiliated Hospital of Wenzhou Medical College, China
    • ,
  • Hua-Fang Su

      Affiliations

    • Department of Radiation Oncology, The First Affiliated Hospital of Wenzhou Medical College, China
    • ,
  • Xia Deng

      Affiliations

    • Department of Radiation Oncology, The First Affiliated Hospital of Wenzhou Medical College, China
    • ,
  • Shi-Xiu Wu

      Affiliations

    • Department of Radiation Oncology, The First Affiliated Hospital of Wenzhou Medical College, China
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China.

Received 23 January 2009 ,Revised 26 July 2009 ,Accepted 11 August 2009.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  2. Jemal A, Murray T, Ward E, et al. Cancer statistics 2005. CA Cancer J Clin. 2005;55:10–30
  3. Koshy M, Esiashvilli N, Landry JC, Thomas CR, Matthews RH. Multiple management modalities in esophageal cancer: combined modality management approaches. Oncologist. 2004;9:147–159
  4. Oehler C, Ciernik IF. Radiation therapy and combined modality treatment of gastrointestinal carcinomas. Cancer Treat Rev. 2006;32:119–138
  5. Ohtsu A. Chemoradiotherapy for esophageal cancer: current status and perspectives. Int J Clin Oncol. 2004;9:444–450
  6. Gupta AK, McKenna WG, Weber CN, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res. 2002;8:885–892
  7. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res. 1999;5:2884–2890
  8. Chakravarti A, Dicker A, Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys. 2004;58:927–931
  9. Contessa JN, Abell A, Valerie K, Lin PS, Schmidt-Ullrich RK. ErbB receptor tyrosine kinase network inhibition radiosensitizes carcinoma cells. Int J Radiat Oncol Biol Phys. 2006;65:851–858
  10. Milas L, Fan Z, Andratschke NH, Ang KK. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys. 2004;58:966–971
  11. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene. 1997;15:1191–1197
  12. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61:3986–3997
  13. Hagan M, Wang L, Harily JR, Park JS, Dent P. Ionizing radiation-induced mitogen-activated protein (MAP) kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiat Res. 2000;153:371–378
  14. Chong G, Cunningham D. The role of cetuximab in the therapy of previously treated advanced colorectal cancer. Semin Oncol. 2005;32:S55–S58
  15. Zhang W, Gordon M, Lenz HJ. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann Med. 2006;38:545–551
  16. Raben D, Helfrich B, Chan DC, et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res. 2005;11:795–805
  17. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  18. Friess H, Fukuda A, Tang WH, et al. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and cerbB-3. World J Surg. 1999;23:1010–1018
  19. Itakura Y, Sasano H, Shiga C, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma: an immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer. 1994;74:795–804
  20. Gibson MK, Abraham SC, Wu TT, et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res. 2003;9:6461–6468
  21. Gotoh M, Takiuchi H, Kawabe S, et al. Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma. Jpn J Clin Oncol. 2007;37:652–657
  22. Shimada Y, Imamura M, Watanabe G, et al. Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology. Br J Cancer. 1999;80:1281–1288
  23. Livak K-J, Schmittgen T-D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408
  24. Russell J, Wheldon TE, Stanton P. A radioresistant variant derived from a human neuroblastoma cell line is less prone to radiation-induced apoptosis. Cancer Res. 1995;55:4915–4921
  25. Giocanti N, Hennequin C, Balosso J, Mahler M, Favaudon V. DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res. 1993;53:2105–2111
  26. Koizumi F, Kanzawa F, Ueda Y, et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer. 2004;108:464–472
  27. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today (Barc). 2005;41:107–127
  28. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer. 2007;96:1166–1169
  29. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–3995
  30. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230–3237
  31. Hollstein MC, Smits AM, Galiana C, et al. Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers. Cancer Res. 1988;48:5119–5123
  32. Arber N, Shapira I, Ratan J, et al. Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology. 2000;118:1045–1050
  33. Hollstein MC, Peri L, Mandard AM, et al. Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. Cancer Res. 1991;51:4102–4106
  34. Safran H, Suntharalingam M, Dipetrillo T, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys. 2008;70:391–395

PII: S0167-8140(09)00445-9

doi: 10.1016/j.radonc.2009.08.008

Radiotherapy & Oncology
Volume 93, Issue 3 , Pages 468-473 , December 2009

Article Tools

* Image Usage & Resolution